IGF-1 LR3
Also referenced as: Array
Neutral technical record and index of the peer-reviewed literature referencing IGF-1 LR3. For research use only — no human or veterinary use, benefit, or dosing information is provided.
What it is
IGF-1 LR3 (Long R3 IGF-1) is a synthetic analogue of insulin-like growth factor 1 carrying an N-terminal extension and an arginine substitution at position 3, which reduce binding to IGF binding proteins. It belongs to the IGF-1 analogue class. It is supplied as lyophilized material for research use only.
Mechanism (technical)
IGF-1 LR3 has been studied in preclinical models for its action through the IGF-1 receptor and downstream anabolic and growth pathways, with the LR3 modifications investigated for altered IGF binding protein interaction. Animal studies examined organ growth, nitrogen balance, and gastrointestinal growth. Adjacent human literature concerns other recombinant IGF-1 forms (mecasermin) rather than LR3 directly.
Peer-reviewed literature
5 studies indexed · 2 human · 3 animal. Listed neutrally; outcome studies are indexed, not endorsed.
- Mecasermin (rhIGF-1) for Rett syndrome: phase 1 trialKhwaja OS, et al. · 2014 · PNAS · clinical trial · human
- Efficacy and safety of mecasermin rinfabateKemp SF, et al. · 2006 · Expert Opin Biol Ther · review · human
- Long R3 IGF-I infusion stimulates organ growth but reduces plasma IGFs in guinea pigConlon MA, et al. · 1995 · J Endocrinol · animal · animal
- IGF-I and variants are anabolic in dexamethasone-treated ratsTomas FM, et al. · 1992 · Biochem J · animal · animal
- IGF-I and N-terminal analogues induce gut growth in dexamethasone-treated ratsRead LC, et al. · 1992 · J Endocrinol · animal · animal
For research use only. Not for human or veterinary use. Not a drug, food, cosmetic, or dietary supplement. Sold to qualified researchers for laboratory research purposes only.